863 results on '"Desai, Jayesh"'
Search Results
2. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
3. From Managed Aquifer Recharge to Managing Aquifer Recharge: Developing a Strategic Approach to Artificial Recharge in India
4. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
5. BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer
6. CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors
7. Bispecific antibodies: advancing precision oncology
8. BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities
9. Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
10. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours
11. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
12. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies
13. A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
14. A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
15. Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
16. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
17. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
18. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm
19. Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.
20. Supplementary Figures from MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors
21. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
22. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
23. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer
24. Clinical activity in general practice before sarcoma diagnosis: an Australian cohort study.
25. The Role of Systemic Therapies in the Management of Soft Tissue Sarcoma
26. Healthcare resource utilisation and costs in patients with advanced soft tissue sarcoma: A data linkage project using a sarcoma referral centre in Australia
27. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN
28. A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours
29. BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
30. New biomarkers for checkpoint inhibitor therapy
31. Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma
32. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer
33. Identifying potential recharge areas of mountain springs through hydrogeological mapping
34. Clinical Impact of Comprehensive Molecular Profiling in Adolescent and Young Adults with Sarcoma
35. Long-term benefit of sotorasib in patients with KRAS G12C–mutated non–small-cell lung cancer: plain language summary
36. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
37. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
38. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
39. The Role of Systemic Therapies in the Management of Soft Tissue Sarcoma
40. BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer.
41. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
42. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
43. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
44. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis
45. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
46. Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model
47. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours
48. Changing trends in phase 1 oncology clinical trials
49. Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma
50. BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.